SUPRIYA

Supriya Lifescience Limited

Specialty APIs and CDMO services for anesthetics and ADHD medicines

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

supriyalifescience.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹886.00
Market cap
7,124 Cr
Stock P/E
35.9
P/B
5.96
Dividend yield
0.1%
ROE (FY26)
17.5%
ROCE (FY26)
23.1%
Operating margin (FY26)
32.1%
OCF / EBITDA (FY26)
63.2%
OCF / EBITDA (3Y)
63.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Supriya Lifescience makes active pharmaceutical ingredients (APIs) and advanced intermediates, selling mainly to pharma customers abroad, with anaesthetics its largest therapy area.

Company snapshot

50thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 25.3% — the business keeps a healthy share of every rupee it earns.
1 more signal from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales140 Cr140 Cr158 Cr161 Cr166 Cr186 Cr184 Cr145 Cr200 Cr206 Cr277 Cr190 Cr
Operating expenses (approx.)108 Cr99 Cr103 Cr98 Cr101 Cr120 Cr117 Cr93 Cr127 Cr134 Cr179 Cr142 Cr
EBITDA32 Cr41 Cr56 Cr63 Cr65 Cr66 Cr68 Cr52 Cr73 Cr72 Cr98 Cr47 Cr
OPM %22.7%29.6%35.1%38.9%39.0%35.5%36.7%35.6%36.4%34.9%35.3%25.0%
Other income2 Cr3 Cr2 Cr2 Cr3 Cr2 Cr3 Cr3 Cr3 Cr3 Cr3 Cr3 Cr
Interest0.46 Cr0.49 Cr0.60 Cr0.34 Cr0.43 Cr0.51 Cr0.42 Cr0.51 Cr0.41 Cr0.49 Cr0.47 Cr0.37 Cr
Depreciation4 Cr4 Cr4 Cr5 Cr5 Cr5 Cr6 Cr6 Cr7 Cr7 Cr8 Cr9 Cr
Profit before tax30 Cr40 Cr53 Cr60 Cr62 Cr63 Cr64 Cr47 Cr68 Cr67 Cr92 Cr41 Cr
Tax %19.8%25.7%30.5%25.3%25.6%25.2%21.4%26.6%26.2%25.8%19.4%41.1%
Net profit24 Cr30 Cr37 Cr45 Cr46 Cr47 Cr50 Cr35 Cr50 Cr50 Cr74 Cr24 Cr
EPS (₹)₹2.97₹3.70₹4.59₹5.54₹5.71₹5.82₹6.29₹4.32₹6.27₹6.17₹9.22₹2.99

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales278 Cr312 Cr385 Cr530 Cr461 Cr570 Cr696 Cr828 CrSign in free for the trailing twelve months
Operating expenses (approx.)213 Cr213 Cr218 Cr316 Cr332 Cr397 Cr436 Cr534 CrSign in free for the trailing twelve months
EBITDA65 Cr98 Cr167 Cr214 Cr129 Cr173 Cr261 Cr294 CrSign in free for the trailing twelve months
OPM %23.3%31.6%43.4%40.4%28.0%30.3%37.4%35.5%Sign in free for the trailing twelve months
Other income8 Cr11 Cr11 Cr8 Cr9 Cr11 Cr10 Cr11 CrSign in free for the trailing twelve months
Interest10 Cr7 Cr4 Cr4 Cr3 Cr2 Cr2 Cr2 CrSign in free for the trailing twelve months
Depreciation5 Cr6 Cr7 Cr10 Cr12 Cr16 Cr20 Cr28 CrSign in free for the trailing twelve months
Profit before tax57 Cr96 Cr167 Cr207 Cr123 Cr166 Cr248 Cr275 CrSign in free for the trailing twelve months
Tax %31.0%23.7%26.0%26.7%27.2%28.1%24.4%23.9%Sign in free for the trailing twelve months
Net profit39 Cr73 Cr124 Cr152 Cr90 Cr119 Cr188 Cr209 CrSign in free for the trailing twelve months
EPS (₹)₹5.39₹10.03₹16.92₹18.86₹11.16₹14.80₹23.35₹25.98Sign in free for the trailing twelve months
Dividend payout %———2.9%5.4%4.1%3.4%3.8%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital15 Cr15 Cr15 Cr16 Cr16 Cr16 Cr16 Cr16 Cr
Reserves79 Cr135 Cr254 Cr600 Cr683 Cr799 Cr981 Cr1,182 Cr
Borrowings85 Cr79 Cr67 Cr21 Cr17 Cr———
Other liabilities74 Cr108 Cr109 Cr98 Cr104 Cr106 Cr116 Cr159 Cr
Total liabilities253 Cr336 Cr446 Cr735 Cr820 Cr921 Cr1,112 Cr1,357 Cr
Fixed assets (net)81 Cr93 Cr96 Cr182 Cr255 Cr304 Cr451 Cr683 Cr
CWIP35 Cr40 Cr79 Cr43 Cr68 Cr149 Cr148 Cr36 Cr
Investments0.05 Cr0.05 Cr0.05 Cr0.05 Cr25 Cr64 Cr63 Cr99 Cr
Loans & advances———0.57 Cr0.55 Cr0.69 Cr0.93 Cr0.57 Cr
Inventories31 Cr49 Cr72 Cr92 Cr116 Cr85 Cr118 Cr160 Cr
Trade receivables60 Cr52 Cr74 Cr115 Cr85 Cr112 Cr134 Cr219 Cr
Cash & bank2 Cr2 Cr31 Cr166 Cr85 Cr68 Cr76 Cr38 Cr
Other assets45 Cr100 Cr94 Cr135 Cr186 Cr139 Cr120 Cr123 Cr
Total assets253 Cr336 Cr446 Cr735 Cr820 Cr921 Cr1,112 Cr1,357 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity49 Cr116 Cr80 Cr49 Cr66 Cr113 Cr165 Cr186 Cr
Cash from investing5 Cr-25 Cr-47 Cr-60 Cr-133 Cr-174 Cr-152 Cr-176 Cr
Cash from financing-50 Cr-29 Cr-15 Cr150 Cr-3 Cr-22 Cr-8 Cr-10 Cr
Net cash flow4 Cr62 Cr18 Cr139 Cr-70 Cr-83 Cr4 Cr-0.29 Cr
Free cash flow (OCF − Capex)—92 Cr33 Cr-11 Cr-42 Cr-32 Cr2 Cr34 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %37.6%45.2%51.0%33.2%17.7%20.6%25.1%23.1%
ROE %42.0%49.2%46.0%24.7%12.8%14.6%18.9%17.5%
Debtor days7961707967717096
Inventory days77118188169225163185219
Days payable110118132901251140152
Cash conversion cycle4562125158167120256163
OCF / EBITDA %75.2%118.0%47.8%22.8%51.3%65.5%63.1%63.2%
OCF / EBITDA % (3 years)——74.0%51.0%38.2%44.3%61.2%63.7%
Debt / equity0.910.530.250.030.02———
Current ratio0.991.271.824.994.855.175.324.40
Net debt / EBITDA1.290.790.22-0.68-0.53-0.40-0.29-0.13